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Abstract
The role of ryanodine receptors (RyRs) in the induction of muscarinic antinociception was investigated in a condition of acute thermal pain
by means of the mouse hot-plate test. I.c.v. administration of non-hyperalgesic doses of ryanodine (0.001–0.06 nmol per mouse i.c.v.), an
antagonist of ryanodine receptors (RyRs), dose-dependently prevented the antinociception induced by both physostigmine (100–150g kg−1
s.c.) and oxotremorine (40–70g kg−1 s.c.). A shift to the right of the dose–response curve of both cholinomimetic compounds was observed.
Pretreatment with non-analgesic doses of 4-chloro-m-cresol (4-Cmc; 0.003–0.3 nmol per mouse i.c.v.), an agonist of RyRs, reversed in a dose-
dependent manner the antagonistic effect produced by ryanodine of muscarinic antinociception. The pharmacological treatments employed
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deither modified the animals’ gross behavior nor produced any behavioral impairment of mice as revealed by the rota-rod and hole-board
ests. These results indicate that a variation of intracellular calcium contents at the central nervous system level is involved in muscarinic
ntinociception. In particular, the stimulation of RyRs appears to play an important role in the increase of the pain threshold produced by
hysostigmine and oxotremorine in mice.
2005 Elsevier B.V. All rights reserved.
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. Introduction
The critical involvement of the cholinergic system in
ain inhibitory pathways has long been known. Several
eports have also provided evidence for the receptorial mech-
nism involved in the muscarinic antinociception. Litera-
ure data indicates that supraspinal cholinergic antinocicep-
ion induced both directly, through muscarinic agonists, and
ndirectly, by enhancing ACh extracellular levels through
holinesterase inhibitors, is mediated by M1 receptor stim-
lation, evidencing that M1 muscarinic receptor subtype
lays an essential role in the modulation of pain percep-
ion [2,11,12,20,23]. The involvement of the M2 muscarinic
eceptor subtype in the induction of analgesia has also been
ostulated by using pharmacological antagonists [13] and by
enerating M2 muscarinic receptor knockout mice [14].
By contrast, little is known about the post-receptorial
vents involved in muscarinic antinociception. It is well
∗ Corresponding author. Tel.: +39 055 4271312; fax: +39 055 4271280.
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established that “odd-numbered” muscarinic receptors
(M1–M3–M5) typically couple via the  subunits of the
Gq/11 family to activate phospholipase C (PLC), stimulat-
ing phosphoinositide (PI) hydrolysis [4]. Receptor-mediated
activation of PLC results in the generation of at least two
messengers, inositol-1,4,5-triphosphate (InsP3) and diacyl-
glicerol (DAG). The main effect of DAG is to activate protein
kinase C (PKC); the effect of InsP3 is to release Ca2+ stored in
the endoplasmic reticulum. The “even-numbered” members
(M2–M4) are preferentially coupled via Gi proteins to inhibit
adenylate cyclase [4]. Expression studies revealed that the
cloned m2 and m4 receptors also stimulate PLC, although
with lower efficiency than the PLC stimulation observed by
m1 or m3 receptors [1].
Calcium ions are widely recognized to play a fundamental
role in the regulation of several biological processes. Tran-
sient changes in cytoplasmic Ca2+ concentration represent
a key step for neurotransmitter release and the modulation
of cell membrane excitability. Evidence has accumulated for
the involvement of Ca2+ also in nociception and antinoci-
ception. On the role of intracellular Ca2+ at a supraspinal166-4328/$ – see front matter © 2005 Elsevier B.V. All rights reserved.
oi:10.1016/j.bbr.2005.06.011
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level, there are several reports indicating its involvement,
sometimes opposed, in the mechanism of action of antinoci-
ceptive drugs in models of acute pain. It is well documented
that agents that increase cytosolic Ca2+ block antinociception
induced by-opioid agonists when injected intracerebroven-
tricularly (i.c.v.) [16,25,32,34]. Furthermore, Ca2+ chelators
or antagonists of L-, N- and P-type Ca2+ channels, potentated
-opioid receptor-mediated antinociception [25,27]. Con-
versely, the antinociception produced by selective -opioid
receptor agonists was potentated by agents that increase intra-
cellular Ca2+ whereas it was reduced by i.c.v. pretreatment
with EGTA [25].
The concentration of intracellular Ca2+ is regulated by
various mechanisms related to physiological functions. One
mechanism is the influx of Ca2+ via Ca2+ channels through
the plasma membrane. Another is the release of Ca2+ from
intracellular stores via intracellular Ca2+-release channels,
the inositol 1,4,5-trisphosphate receptor (InsP3R) and the
ryanodine receptor (RyR): InsP3R is a key molecule for
InsP3-induced Ca2+ release, whereas RyR is important for
Ca2+-induced Ca2+ release [7,22].
Recently, the involvement of intracellular calcium con-
tents in the supraspinal antinociception produced by choli-
nomimetic drugs has been investigated. It has been reported
that muscarinic antinociception requires the activation of the
PLC-InsP pathway. In particular, pretreatment with com-
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from KW Mechanical Workshop, Siena, Italy. Reaction times (s),
were measured with a stopwatch before and 15, 30, 45 and 60 min
after administration of analgesic drugs. The endpoint used was the
licking of the fore or hind paws. Those mice scoring less than 12 and
more than 18 s in the pretest were rejected (30%). An arbitrary cut-
off time of 45 s was adopted. No sign of tissue injury was observed
up to 45 s. At least two independent replications of 7 mice each were
performed (14 mice per treatment).
2.3. Rota-rod test
The apparatus consisted of a base platform and a rotating rod
with a diameter of 3 cm and a non-slippery surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm in length,
was divided into 5 equal sections by 6 disks. Thus, up to 5 mice
were tested simultaneously on the apparatus, with a rod-rotating
speed of 16 rpm. The integrity of motor coordination was assessed
on the basis of the number of falls from the rod in 30 s according to
Vaught et al. [33]. Those mice scoring less than 3 and more than 6
falls in the pretest were rejected (20%). The performance time was
measured before (pretest) and 15, 30 and 45 min after the beginning
of the test. Ten mice per group were tested.
2.4. Hole-board test
The hole-board test consisted of a 40 cm square plane with 16
flush mounted cylindrical holes (3 cm diameter) distributed 4× 4
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ounds that inhibit the increase of intracellular Ca2+ levels
hrough a blockade of InsP3R-mediated pathway prevented
uscarinic antinociception in mice [9]. However, it should
lso be taken into account the important role-played by RyRs
n the modulation of the intracellular calcium levels. In order
o further elucidate the post-receptorial events involved in
entral muscarinic antinociception, the aim of the present
tudy was to investigate the involvement of RyRs in the mech-
nism of action of cholinomimetic drugs at a supraspinal level
n an animal model of acute thermal pain.
. Methods
.1. Animals
Male Swiss albino mice (22–24 g) from Morini (San Polo
’Enza, Italy) were used. Ten mice were housed per cage. The
ages were placed in the experimental room 24 h before the test
or acclimatization. The animals were fed a standard laboratory diet
nd tap water ad libitum and kept at 22± 1 ◦C with a 12 h light/dark
ycle, light at 7 a.m. All experiments were carried out in accordance
ith the NIH Guide for the Care and Use of Laboratory animals.
ll efforts were made to minimize animal suffering, and to reduce
he number of animals used.
.2. Hot-plate test
The method adopted was described by O’Callaghan and Holtz-
an [24]. Mice were placed inside a stainless steel container, which
as set thermostatically at 52.5± 0.1 ◦C in a precision water-bathn an equidistant, grid-like manner. Mice were placed on the cen-
er of the board one by one and allowed to move about freely
or a period of 5 min each. Two electric eyes, crossing the plane
rom mid-point to mid-point of opposite sides, thus dividing the
lane into 4 equal quadrants, automatically signaled the move-
ent of the animal (counts in 5 min) on the surface of the plane
spontaneous motility). Miniature photoelectric cells, in each of
he 16 holes, recorded (counts in 5 min) the exploration of the
oles (exploratory activity) by the mice. Ten mice per group were
ested.
.5. I.c.v. injection technique
I.c.v. administration was performed under ether anesthesia with
sotonic saline as solvent, according to the method described by
aley and McCormick [15]. During anesthesia, mice were grasped
rmly by the loose skin behind the head. A hypodermic needle
0.4 mm external diameter) attached to a 10l syringe was inserted
erpendicularly through the skull and no more than 2 mm into the
rain of the mouse, where 5l solution were then administered. The
njection site was 1 mm to the right or left from the midpoint on a
ine drawn through to the anterior base of the ears. Injections were
erformed randomly into the right or left ventricle. To ascertain that
olutions were administered exactly into the cerebral ventricle, some
ice were injected with 5l of diluted 1:10 India ink and their brains
ere examined macroscopically after sectioning. The accuracy of
he injection technique was evaluated with 95% of injections being
orrect.
.6. Drugs
The following drugs were used: ryanodine, 4-chloro-m-
resol, (Calbiochem, Milan Italy); physostigmine hemisulphate,
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oxotremorine methiodide (Sigma, Milan, Italy). Other chemicals
were of the highest quality commercially available.
4-Chloro-m-cresol (4-Cmc) was dissolved in 0.5% ethanol
whereas all other drugs were dissolved in isotonic (NaCl 0.9%)
saline solution immediately before use. Drug concentrations were
prepared so that the necessary dose could be administered in a vol-
ume of 5l per mouse by intracerebroventricular (i.c.v.) injection
and 10 ml kg−1 by subcutaneous (s.c.) injection.
2.7. Statistical analysis
All experimental results are given as the mean±S.E.M. An
analysis of variance ANOVA, followed by Fisher’s protected least
significant difference procedure for post hoc comparison, were used
to verify significance between two means of behavioral results. Data
were analyzed with the StatView software for the Macintosh (1992).
P-values of less than 0.05 were considered significant.
3. Results
3.1. Prevention by ryanodine of muscarinic
antinociception
The effect of the RyR antagonist ryanodine on muscarinic
antinociception against an acute thermal stimulus was eval-
uated by means of the mouse hot-plate test.
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Ryanodine, when injected alone at the highest effective
dose (0.06 nmol per mouse i.c.v.) was unable to modify the
licking latency values of animals in comparison with saline-
treated control group (Fig. 1A).
The licking latency values reported in Figs. 1 and 2
were recorded in correspondence with physostigmine and
oxotremorine maximum effect (15 min after administration)
as evidenced by time-course experiments performed in our
laboratory (data not shown).
3.2. Reversal of 4-Cmc of the ryanodine-induced
antagonistic effect on muscarinic antinociception
The administration of the RyR agonist 4-Cmc (0.003–
0.1 nmol per mouse i.c.v.) produced a dose-dependent rever-
sal of the antagonistic effect induced by pretreatment with
ryanodine of the muscarinic antinociception (Figs. 3 and 4).
The licking latency values reported in the figure were
recorded 120 min after administration of 4-Cmc in correspon-
Fig. 1. Panel A: dose–response curve of the antagonism produced by ryan-
odine (0.001–0.06 nmol per mouse i.c.v.) of the antinociception induced
by physostigmine (100–150g kg−1 s.c.) in the mouse hot-plate test. The
licking latency values were recorded 15 min after physostigmine adminis-
tration. Vertical lines represent S.E.M. ◦P< 0.05, ◦◦P< 0.01, ◦◦◦P< 0.001
in comparison with saline-treated group; **P< 0.01 in comparison with
physostigmine-treated group. Panel B: shift to the right of the dose–response
curve of physostigmine by ryanodine 0.06 nmol per mouse i.c.v. in the
mouse hot-plate test. The licking latency value were recorded 15 min after
physostigmine administration. Vertical lines represent S.E.M. *P< 0.05,
**P< 0.01 in comparison with physostigmine-treated group.Physostigmine, administered at the dose of 100g kg−1
.c. induced an antinociceptive effect, which was prevented
y i.c.v. administration of ryanodine in a dose-dependent
anner. The doses of 0.001 and 0.01 nmol per mouse i.c.v.
ere devoid of any effect. At 0.03 nmol per mouse i.c.v. ryan-
dine produce a reduction of the licking latency, which did
ot reach the statistical significance, whereas at 0.06 nmol
er mouse i.c.v ryanodine antagonized the increase of the
ain threshold. Similarly, ryanodine at 0.06 nmol per mouse
.c.v. prevented the antinociception induced by physostig-
ine injected at the dose of 150g kg−1 s.c. (Fig. 1A). A
hift to the right of the dose–response curve of physostig-
ine by administration of ryanodine at 0.06 nmol per mouse
.c.v. is reported in Fig. 1B.
Oxotremorine (40–70g kg−1 s.c.) increase the licking
atency values in the mouse hot-plate test. Pretreatment with
yanodine dose-dependently prevented this antinociceptive
ffect. Ryanodine administered at the dose of 0.001 nmol
er mouse i.c.v. was unable to modify the oxotremorine-
nduced antinociception whereas, at the dose of 0.06 nmol per
ouse i.c.v. it produced a statistically significant prevention
f the oxotremorine-induced increase of the pain threshold
Fig. 2A). A shift to the right of the dose–response curve
f oxotremorine by administration of ryanodine at 0.06 nmol
er mouse i.c.v. is reported in Fig. 2B.
Ryanodine, at the dose of 0.06 nmol/mouse i.c.v., was
nable to prevent the analgesia induced by diphenhydramine
0 mg kg−1 s.c. (diph. + saline: 28.4± 3.3; diph. + ryan.:
9.8± 2.9) and by baclofen 4 mg kg−1 s.c. (bacl. + saline:
3.0± 2.0; bacl. + ryan: 32.1± 3.5).
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Fig. 2. Panel A: dose–response curve of the antagonism produced by ryan-
odine (0.001–0.06 nmol per mouse i.c.v.) of the antinociception induced
by oxotremorine (40–70g kg−1 s.c.) in the mouse hot-plate test. The
licking latency value were recorded 15 min after oxotremorine adminis-
tration. Vertical lines represent S.E.M. ◦P< 0.05, ◦◦P< 0.01, ◦◦◦P< 0.001
in comparison with saline-treated group; *P< 0.05, **P< 0.01 in compar-
ison with oxotremorine-treated group. Panel B: shift to the right of the
dose–response curve of oxotremorine by ryanodine 0.06 nmol per mouse
i.c.v. in the mouse hot-plate test. The licking latency value were recorded
15 min after oxtremorine administration. Vertical lines represent S.E.M.
*P< 0.05, **P< 0.01 in comparison with oxotremorine-treated group.
Fig. 3. Reversal by 4-Cl-m-cresol (4-Cmc) of the antagonism produced by
ryanodine (0.06 nmol per mouse i.c.v.) of the physostigmine (100g kg−1
s.c.)-induced antinociception. Vertical lines represent S.E.M. ◦◦P< 0.01,
◦◦◦P< 0.001 in comparison with saline-treated group; *P< 0.05, **P< 0.01
in comparison with physostigmine-treated group.
Fig. 4. Reversal by 4-Cl-m-cresol (4-Cmc) of the antagonism produced by
ryanodine (0.06 nmol per mouse i.c.v.) of the oxotremorine (50–70g kg−1
s.c.)-induced antinociception. Vertical lines represent S.E.M. ◦◦P< 0.01,
◦◦◦P< 0.001 in comparison with saline-treated group; *P< 0.05 in com-
parison with oxotremorine-treated group.
dence with its maximum effect as evidenced by time-course
experiments (data not shown).
The doses of 4-Cmc of 0.003 and 0.03 nmol per mouse
i.c.v. were completely ineffective on modifying the antago-
nism induced by ryanodine (0.06 nmol per mouse i.c.v) of
physostigmine (100g kg−1 s.c.) antinociception. The dose
of 4-Cmc of 0.06 nmol per mouse i.c.v. produced a partial
reversal without reaching the statistical significance, whereas
the dose of 0.1 nmol per mouse i.c.v. reversed the ryanodine-
induced antagonism of the physostigmine-induced antinoci-
ceptive effect (Fig. 2). Similarly, 4-Cmc dose-dependently
reversed the prevention of the antagonism of oxotremorine
(50, 60 and 70g kg−1 s.c.) antinociception by pretreatment
with ryanodine. The dose of 4-Cmc of 0.03 nmol was devoid
of any effect, the dose of 0.1 nmol per mouse i.c.v. produced
a non-significant partial reversal, whereas at 0.3 nmol per
mouse i.c.v. abolished the antagonism produced by ryanodine
(Fig. 4).
4-Cmc, when injected alone at the highest doses investi-
gated did not modify the pain threshold of animals in com-
parison with the control group (Fig. 3).
3.3. Effect of treatments on mouse behaviour
The compounds investigated, at the highest effective
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ooses, were tested in order to assess their effect on mouse
ehavior. Mice pretreated with ryanodine (0.06 nmol per
ouse i.c.v.), 4-Cmc (0.3 nmol per mouse i.c.v.), physostig-
ine (150g kg−1 s.c.) and oxotremorine (70g kg−1 s.c.)
ere evaluated for motor coordination by use of the rota-rod
est, and for spontaneous motility and inspection activity by
se of the hole-board test.
The spontaneous motility as well as the inspection activ-
ty of mice, expressed as counts in 10 min, were unmodified
y pretreatment with ryanodine, 4-Cmc, physostigmine and
xotremorine in comparison with control group (Fig. 5).
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Fig. 5. Lack of effect by ryanodine (0.06 nmol per mouse i.c.v.), 4-
Cmc (0.03 nmol per mouse i.c.v.), physostigmine (150g kg−1 s.c.) and
oxotremorine (70g kg−1 s.c.) on spontaneous motility and inspection activ-
ity in the mouse hole-board test. Vertical lines represent S.E.M. 4-Cmc
was injected 105 min before the beginning of the test, whereas ryanodine,
physostigmine and oxotremorine were administered 15 min before the begin-
ning of the test.
The number of falls from the rotating rod, evaluated before
and 15, 30 and 45 min after the beginning of the rota-rod test,
showed the lack of any impairment in the motor coordination
of animals pretreated with all pharmacological modulators in
comparison with the control group (Fig. 6).
Fig. 6. Lack of effect by ryanodine (0.06 nmol per mouse i.c.v.), 4-
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4. Discussion
The present study investigated the role of ryanodine recep-
tors in the supraspinal muscarinic antinociception in a con-
dition of acute thermal pain in mice. The importance of the
activation of the RyR-mediated pathway to obtain an increase
of the pain threshold by cholinomimetic drugs was evidenced.
Ca2+ plays an important role in a variety of central and
peripheral physiological processes. To avoid the possible
appearance of peripheral effects that could lead to a mis-
interpretation of the results obtained, the Ca2+ modulators
used in the present study were administered directly into the
cerebral ventricles.
The release of Ca2+ from intracellular stores is mediated
via intracellular Ca2+-release channels, the inositol 1,4,5-
trisphosphate receptor (InsP3R) and the ryanodine receptor
(RyR): InsP3R is a key molecule for InsP3-induced Ca2+
release, whereas RyR is important for Ca2+-induced Ca2+
release. The involvement of InsP3R in the mechanism of anal-
gesic action of cholinomimetics has already been observed
[9]. Since both receptor subtypes are involved in intracellular
calcium mobilization, in the present study the role played by
RyRs in muscarinic antinociception was investigated.
The i.c.v. administration of ryanodine produced a
dose-dependent prevention of the physostigmine- and
oxotremorine-induced antinociception in mice. A shift to
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emc (0.03 nmol per mouse i.c.v.), physostigmine (150g kg s.c.) and
xotremorine (70g kg−1 s.c.) on motor coordination in the mouse rota-rod
est. Vertical lines represent S.E.M. 4-Cmc was injected 105 min before the
eginning of the test, whereas ryanodine, physostigmine and oxotremorine
ere administered 15 min before the beginning of the test. Vehicle: 0.5%
thanol.he right of the dose–response curve of both cholinomimetic
rugs was observed. These data indicate the involvement of
yRs in the induction of muscarinic antinociception. Present
esults are in agreements with previous literature reports indi-
ating the involvement of RyRs in the mechanism of action
f analgesic drugs. Ohsawa et al. [25] showed that ryanodine
educed the antinociception induced by the delta opioid ago-
ist (−)-TAN67 in diabetic mice. It has been reported that
yanodine blocks Ca2+ release from Ca2+/caffeine-sensitive
icrosomal pools, which are involved in the phenomenon
f Ca2+-induced Ca2+ release [21]. Ryanodine reduces the
ate at which [Ca2+]i increase with Ca2+ entry [8]. Thus,
t seems likely that the antagonism of the cholinomimetic
rug-induced antinociception produced by i.c.v. ryanodine
ight be due to a decrease of [Ca2+]i at supraspinal level.
hysostigmine, acting as a cholinesterase inhibitor, pro-
uces an increase of the ACh levels, which, on their turn,
an activate both muscarinic and nicotinic receptors. It has
een reported that nicotinic antinociception depends on an
ncrease of the intracellular calcium contents. Pretreatment
ith calcium, BAYK8644 and thapsigargin, compounds that
ncrease the intracellular calcium levels, potentated nicotine-
nduced antinociception, whereas agents that decrease intra-
ellular calcium blocked the increase of the pain threshold
nduced by nicotine [6]. Furthermore, the nicotine-evoked
alcium response in SH-SY5Y is blocked by ryanodine
nd xestospongin C (an antagonist of InsP3R) indicating
hat it involves calcium release from ryanodine and InsP3-
ependent intracellular stores [5]. However, ryanodine, in our
xperimental conditions prevented not only physostigmine-
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induced but also oxotremorine-induced increase of pain
threshold suggesting that the release of Ca2+ from intra-
cellular stores produced by RyR activation is necessary to
induce muscarinic antinociception. It should also be noted
that an increased intracellular calcium mobilization through
RyR activation has been demonstrated after stimulation of
muscarinic receptors. Carbachol-evoked increase of intracel-
lular calcium concentration in cerebellar granule cells was
inhibited by ryanodine [30]. Activation of muscarinic acetyl-
choline receptors in NG108-15 neuroblastoma× glioma cells
produces cyclic ADP-ribose, a known endogenous modulator
of RyR, which may upregulate the release of calcium from
the ryanodine receptors [18,19]. Carbachol-induced contrac-
tions of rat stomach fundus strips were reduced by ryanodine
and thapsigargin [31]. Similarly, ryanodine blocked the early
contraction component increased by carbachol in guinea pig
ventricular myocytes [28].
The prevention of physostigmine and oxotremorine
antinociception produced by ryanodine was dose-
dependently reversed by co-administration of chloro-m-
cresol (4-Cmc), an agonist of RyR [17], further suggesting
the involvement of RyRs in muscarinic antinociception. It
should also be taken into account that compounds able to
activate RyR, such as caffeine, are endowed with central
antinociceptive properties [10,26,29].
The highest active doses of ryanodine used in the present
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the results obtained were due to animals’ altered viability. It
should be noted that higher doses of cholinomimetics could
not be investigated since they induced toxicity (tremors, con-
vulsions, etc.) in animals.
Seen as a whole present results indicate that the variation
of cytosolic Ca2+ contents at supraspinal level by modulating
RyR is involved in the muscarinic antinociception evaluated
in an acute thermal pain paradigm. In particular, a decrease
of cytosolic Ca2+ through the blocked of RyR prevents mus-
carinic antinociception whereas an increase of intracellular
Ca2+ induced by RyR activation restores the sensitivity to
cholinomimetic drugs of animal pretreated with a RyR antag-
onist.
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